Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research Ltd (LICR)is a global non profit committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Clinical Research
Targeted Antibodies
Dr. Andrew Scott (pictured), Director of the LICR Melbourne Centre, is using positron emission tomography (PET) to non-invasively monitor the tumor targeting and pharmacokinetics of one of LICR's targeted antibodies, which has been labeled with a trace amount of radioisotope and injected into the patient. More »